Advertisement
Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Drug Promising as Potential Anemia Treatment

August 27, 2014 2:21 pm | News | Comments

An experimental drug designed to help regulate the blood’s iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment. Read more...         

Merck Serono Breaks Ground on New China Facility

August 27, 2014 11:09 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China. Read more...                       

EC Approves BMS Drug as Hep C Combo Treatment

August 27, 2014 11:03 am | News | Comments

Bristol-Myers Squibb Co. announced that the European Commission has approved Daklinza (daclatasvir) for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read more...

Advertisement

Targeted Neuroblastoma Therapy One Step Closer

August 27, 2014 10:52 am | News | Comments

Researchers have uncovered new targets for therapy in the childhood cancer neuroblastoma, bringing hope for the development of novel treatments. Read more...                           

New Statin Guidelines are an Improvement, Study Shows

August 26, 2014 3:18 pm | News | Comments

New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease, a study has found. Read more...                             

FDA Approves Additional Promacta Indication

August 26, 2014 3:14 pm | News | Comments

GSK announced that the FDA has approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). Read more...

Alkermes Launches Phase 1 Pain Treatment Study

August 26, 2014 3:08 pm | News | Comments

Alkermes plc announced the initiation of a Phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain. Read more...                       

Kite Pharma's Lymphoma Drug Excels in Trial

August 26, 2014 3:03 pm | News | Comments

Shares of Kite Pharma surged before markets opened Tuesday after the drug developer detailed promising results for its most advanced product, a potential treatment for an aggressive form of non-Hodgkin's lymphoma. Read more...       

Advertisement

Pfizer, Merck to Explore Novel Anti-Cancer Combo

August 26, 2014 2:55 pm | News | Comments

Pfizer Inc. and Merck & Co. Inc. announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab. Read more...   

Cancer-Fighting Drugs Might Also Stop Malaria Early

August 26, 2014 2:47 pm | News | Comments

Scientists searching for new drugs to fight malaria have identified a number of compounds- some of which are currently in clinical trials to treat cancer- that could add to the anti-malarial arsenal. Read more...            

Drug Cured 16 of 16 Monkeys with Viral Ebola Relative

August 26, 2014 11:31 am | by Cynthia Fox, Science Editor | Articles | Comments

An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...                   

Cardiome, Eurolab Partner on Brinavess Distribution

August 26, 2014 11:00 am | News | Comments

Cardiome Pharma Corp. announced that its subsidiary, Correvio International Sàrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute Brinavess exclusively in Argentina. Read more…    

New Ebola Vaccine Study Delivers Promising Results

August 26, 2014 10:44 am | News | Comments

Immunovaccine Inc. announced positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Read more...

Advertisement

Avanir Launches Phase 2 MDD Drug Study

August 26, 2014 10:23 am | News | Comments

Avanir Pharmaceuticals Inc. announced the enrollment of the first patient into a Phase 2 study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). Read more...     

Regado Biosciences Permanently Halts Phase 3 Trial

August 25, 2014 3:08 pm | News | Comments

Regado Biosciences Inc. announced the permanent termination of enrollment in its REGULATE-PCI Phase 3 trial for its lead program, Revolixys Kit. Read more...                           

Zorvolex Approved for Management of Osteoarthritis Pain

August 25, 2014 3:03 pm | News | Comments

Iroko Pharmaceuticals LLC announced that the FDA has approved Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain. Read more...                 

FDA Gives Insys Pharmaceutical Cannabidiol Orphan Status

August 25, 2014 2:57 pm | News | Comments

Insys Therapeutics Inc. announced that the FDA has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM). Read more...                 

Vivus Acquires Patent Rights to Qsymia Ingredient

August 25, 2014 2:51 pm | News | Comments

Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals. Read more...                            

DNA Repair Drug Could Help Treat Leukemia, Other Cancers

August 25, 2014 10:19 am | News | Comments

A team of scientists found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukemia and other cancers. Read more...              

Japan Ready to Offer Flu Drug for Ebola Treatment

August 25, 2014 9:54 am | by Mari Yamaguchi | News | Comments

Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak. Read more...                         

‘The Pill’ Shrinks Ovaries, Cuts Egg Numbers

August 25, 2014 9:49 am | by Cynthia Fox, Science Editor | Articles | Comments

The birth control pill significantly affects ovarian reserve— or the number of immature eggs in a woman’s ovaries— which can be a predictor of future fertility, according to a team in Denmark. Read more...             

Alabama Ruling on Drug Warnings Draws Suspicion

August 23, 2014 11:25 am | by Jay Reeves | News | Comments

Business isn't buying the Alabama Supreme Court's attempt to limit the fallout from its decision saying brand-name drugmakers can be held liable for warnings on generic medication produced by other companies. Read more...         

Baxter's Hemophilia Drug Hits Phase 3 Endpoint

August 22, 2014 4:05 pm | News | Comments

Baxter International Inc. announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A. Read more...          

Janssen, ViaCyte Partner on Potential Diabetes Treatment

August 22, 2014 3:55 pm | News | Comments

ViaCyte Inc., a privately held regenerative medicine company announced that it has entered into a Rights Agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Read more...   

Mylan Launches First Generic Klor-Con Extended-Release Tablets

August 22, 2014 3:46 pm | News | Comments

Mylan Inc. announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con. Read more...                

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading